Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phase I studies of drug combinations.

× No keyword cloud information.

8 in total

1. American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.

Authors: Jeffrey S Weber; Laura A Levit; Peter C Adamson; Suanna Bruinooge; Howard A Burris; Michael A Carducci; Adam P Dicker; Mithat Gönen; Stephen M Keefe; Michael A Postow; Michael A Thompson; David M Waterhouse; Susan L Weiner; Lynn M Schuchter
Journal: J Clin Oncol Date: 2014-12-15 Impact factor: 44.544

Review 2. Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.

Authors: César Serrano; Suzanne George; Claudia Valverde; David Olivares; Alfonso García-Valverde; Cristina Suárez; Rafael Morales-Barrera; Joan Carles
Journal: Target Oncol Date: 2017-06 Impact factor: 4.493

3. Dose-finding designs for trials of molecularly targeted agents and immunotherapies.

Authors: Cody Chiuzan; Jonathan Shtaynberger; Gulam A Manji; Jimmy K Duong; Gary K Schwartz; Anastasia Ivanova; Shing M Lee
Journal: J Biopharm Stat Date: 2017-02-06 Impact factor: 1.051

4. Characteristics of drug combination therapy in oncology by analyzing clinical trial data on ClinicalTrials.gov.

Authors: Menghua Wu; Marina Sirota; Atul J Butte; Bin Chen
Journal: Pac Symp Biocomput Date: 2015

5. Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.

Authors: Peter H O'Donnell; Sanja Karovic; Theodore G Karrison; Linda Janisch; Matthew R Levine; Pamela J Harris; Blase N Polite; Ezra E W Cohen; Gini F Fleming; Mark J Ratain; Michael L Maitland
Journal: Clin Cancer Res Date: 2015-07-21 Impact factor: 12.531

Review 6. Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991-2015.

Authors: Kota Itahashi; Toshio Shimizu; Takafumi Koyama; Shunsuke Kondo; Yutaka Fujiwara; Noboru Yamamoto
Journal: Invest New Drugs Date: 2018-08-07 Impact factor: 3.850

7. Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LH(BETA)T(AG) retinal tumors.

Authors: Y Piña; C Decatur; Tg Murray; Sk Houston; D Gologorsky; M Cavalcante; L Cavalcante; E Hernandez; M Celdran; W Feuer; T Lampidis
Journal: Clin Ophthalmol Date: 2011-03-07

8. An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma.

Authors: Amélie Anota; Mathieu Boulin; Sandrine Dabakuyo-Yonli; Patrick Hillon; Jean-Pierre Cercueil; Anne Minello; Jean-Louis Jouve; Xavier Paoletti; Laurent Bedenne; Boris Guiu; Franck Bonnetain
Journal: BMJ Open Date: 2016-06-24 Impact factor: 2.692

8 in total